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Aptamers are single-stranded oligonucleotides that bind to targets with high aﬃnity and selectivity. Their use as molecular
recognition elements has emerged as a viable approach for biosensing, diagnostics, and therapeutics. Despite this potential,
relatively few aptamers exist that bind to small molecules. Small molecules are important targets for investigation due to their
diverse biological functions as well as their clinical and commercial uses. Novel, eﬀective molecular recognition probes for these
compounds are therefore of great interest. This paper will highlight the technical challenges of aptamer development for small
molecule targets, as well as the opportunities that exist for their application in biosensing and chemical biology.
1. Aptamers as Molecular Recognition Elements
Historically, nucleic acids were associated with the storage
and genetic coding of information and have long been
thought to be less complex than proteins [1]. However, like
proteins, nucleic acids are able to fold into intricate tertiary
structures that have the potential to perform a variety of
functions including gene-regulation, catalytic activity and
ligand-binding [2]. Interest in these so-called “functional”
nucleic acids was prompted by the ever-increasing number of
discoveries of non-coding ribonucleic acids (RNAs) display-
ing catalytic or binding properties [2].
Two decades ago, several researchers revolutionized
molecular recognition by developing synthetic RNA motifs
that bound specifically to molecular targets [3–5]. These
RNA structures, called aptamers, were selected using an
in vitro selection procedure called systematic evolution of
ligands by exponential enrichment (SELEX) [3]. Like anti-
bodies, these synthetically derived molecular recognition
probes were found to be selective and able to bind to their
targets with high aﬃnity.
Currently, there is a growing need for rapid, robust, and
inexpensive methods for sensing and diagnostic purposes
[6]. As molecular recognition is the cornerstone of sensing,
there has been increased focus on the development of
new molecular recognition probes for sensing applications
[7]. While antibodies have long been considered to be the
standard in molecular recognition and the use of antibodies
as recognition probes predates the 1950s, the relatively
new technology of aptamers oﬀers several advantages [8].
Firstly, the in vitro aptamer selection process allows a greater
control over aptamer binding conditions. Nonphysiological
salt concentrations, temperatures and pH can be used in
successful selections [9]. Due to the robustness of the phos-
phodiester backbone, aptamers can exhibit an improved
stability over their protein-based antibody counterparts. In
particular, aptamers can be reversibly denatured by changing
the surrounding conditions. For example, a change in pH,
temperature, ionic strength, or use of denaturants irreversi-
bly denatures antibodies, while aptamers simply unfold.
The aptamer structure can then regain functionality upon
return of the original binding conditions [6]. Due to the
nucleic acid nature of aptamers, they bind to complementary
nucleic acids as well as their targets, which can be exploited
in sensing schemes or as “antidotes” in vivo. Aptamer
generation has been achieved for a wide variety of targets
including small molecules [10], proteins [11], viruses [12],
and whole cells [13]. Unlike antibodies, aptamers can also
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be generated for targets that are toxic as well as for targets
that do not elicit an immune response in vivo [8]. Once
selected, aptamers are manufactured using well-established
automated chemical solid-phase synthesis [14, 15]. The
accuracy and reproducibility of this procedure allows for a
relative ease in producing aptamers at large scales, with very
little batch-to-batch variation in activity [16]. Additionally,
aptamer sequences can be modified with reporter molecules
throughout this solid-phase synthesis; this allows for labeling
at judiciously chosen nucleotide positions to minimize any
eﬀect on the functionality of the aptamer [17, 18].
Aptamers also oﬀer advantages over other synthetically
created molecular recognition systems such as molecular
imprinted polymers (MIPs). While MIP synthesis can be
simple and cheap, and the resulting MIPs are unaﬀected by
changes in heat and pH [19], MIPs typically display high
cross-reactivity [20] and are not particularly amenable to
chemical modifications.
Of course, aptamers are not without their disadvantages.
Unlike antibodies or MIPS, their tertiary structure is highly
dependent on solution conditions, and they are easily deg-
raded in blood. Furthermore, antibodies have a significantly
higher chemical diversity with 20 amino acids. However,
some of these problems can be addressed, for example,
through chemical modifications to increase nuclease resis-
tance or increase the diversity of the nucleic acid pools.
1.1. Systematic Evolution of Ligands by Exponential Enrich-
ment (SELEX). The concept of in vitro evolution was first
reported in the 1960s with the observation that, in a cell-
free system, the RNA genome of the Qβ bacteriophage could
be evolved during replication to form RNAs that were more
eﬃciently copied by the viral replicase [21]. Later, they were
able to evolve sequences for other traits such as resistance
to ethidium bromide [22]. Despite the importance of these
early discoveries, however, the true potential of in vitro
evolution was not realized until several decades later, after
the introduction of modern biotechnological advances such
as the invention of polymerase chain reaction (PCR), the
isolation of reverse transcriptase and the ability to generate
long oligonucleotides containing random nucleotide regions
using solid-phase synthesis. Equipped with these modern
techniques, in 1990, three separate groups reported in vitro
selection and evolution of functional nucleic acids [23].
Tuerk and Gold [3] used the term SELEX for their process of
selecting RNA ligands against T4 DNA polymerase; Ellington
and Szostak [4] performed in vitro selection to select RNA
ligands (for which they coined the term “aptamers”) against
various organic dyes; Robertson and Joyce [5] evolved the
Tetrahymena self-splicing intron to carry out a DNA cleavage
reaction.
Since its invention, several researchers have performed
SELEX to isolate nucleic acids with a wide variety of
functions. While several modifications of the procedure have
been made by various groups, the general SELEX process
remains the same (Figure 1 shows the process for DNA
aptamers). Typically, SELEX begins with an initial library
(often referred to as “a pool”) of random nucleic acid
sequences (either RNA or DNA depending on the nature
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Figure 1: The systematic evolution of ligands by exponential enri-
chment process (SELEX). Beginning with a large library of DNA,
iterative cycles of target incubation, library partitioning, and ampli-
fication are performed to select aptamers.
of the research). SELEX libraries ideally consist of 30–80
random nucleotide positions flanked by primer-binding sites
necessary for PCR amplification [24]. The library is then
incubated with the target of interest and several washing
steps are employed to remove nonfunctional sequences. For
small molecule targets, the target is usually immobilized onto
a solid-support matrix to permit partitioning of binding and
nonbinding sequences [25]. The next steps in SELEX include
the elution of the binding sequences from the target and
the polymerase chain reaction (PCR) amplification (reverse
transcription PCR for the RNA aptamers) of those binding
sequences to yield an enriched library for subsequent, more
stringent, selection rounds [10]. As the interactions that
lead to molecular recognition between the binding sequences
and the target are noncovalent in nature, mild conditions
can be used to separate the two species. Elution using heat,
high concentrations of the target molecule, or chaotropic
agents, such as urea, can be performed. The strength of the
molecular interactions within the target-aptamer complex
will dictate the conditions required for elution [7].
Once separated from the target, the few binding DNA
sequences are amplified by PCR to yield a practical amount
of sample to continue the process. As PCR generates double-
stranded DNA and aptamers are single stranded, the DNA
aptamer sequence is separated from its complement using
one of a number of techniques, such as gel electrophoresis
or using an agarose resin [26, 27]. Single-stranded RNA
aptamers are generated from the double-stranded DNA PCR
products by in vitro transcription [10], thus no further
processing is required before reintroduction of an enriched
RNA pool into the next SELEX round.
SELEX progress can be monitored by modifying the
aptamer strand with a traceable label, to determine when
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more stringent conditions should be applied [28]. The
enriched library generated from a round of selection is
subjected to further selection rounds that serve to increase
the aﬃnity of the library for the target molecule (positive
selections). After several rounds, the enriched library is
cloned, sequenced and characterized to isolate aptamers with
the desired properties. Once these sequences are elucidated,
solid-phase chemical synthesis is used to reproducibly syn-
thesize aptamers in large quantities.
1.2. Adaptations to the SELEX Process. An enormous advan-
tage of SELEX is its flexibility with respect to methodology,
binding conditions and library design. The first SELEXmod-
ifications introduced the inclusion of negative or counter
selection steps to eliminate sequences displaying aﬃnity
for either the solid-support matrix or compounds sharing
structural similarity to the target. The majority of more
recent SELEX modifications involve changing the stringency,
the platform on which selection is performed or the type
of target [29, 30]. The library used in the selection can also
be modified to include fixed regions of known functionality
or increase the diversity of structures available for selection
either through initial pool design [28, 31, 32], or by inclusion
of mutagenic PCR to alter the pool from round to round
[33]. The SELEX process has also been automated by several
groups [34–36]. Table 1 lists several modifications to the
original SELEX process. Regardless of whether the listed
SELEXmodifications involved changes to target immobiliza-
tion, nucleic acid library, selection stringency, amplification,
or monitoring of the enrichment, the goal of these changes
was to either generate improved aptamers or to simplify the
SELEX procedure.
2. SELEX Targets
As can be noted from Figure 2, less than a quarter of existing
aptamers have been generated for small molecule targets.
With the success of the first in vitro selection experiments
to small organic dyes [4], much of the original SELEX focus
was on developing aptamers for small molecules. However,
once it was found that aptamers could be easily selected for
proteins and cells, new aptamers for small molecules became
less prevalent. These larger targets, containing more func-
tional groups and structural motifs, give a higher probability
of finding sequences that can interact with the target via
hydrogen bonds, electrostatic interactions, and hydrophobic
interactions [6].
2.1. Small Molecule-Binding Aptamers. Despite this trend
towards larger targets, there are many compelling reasons for
pursuing the identification of new small molecule-binding
aptamers. Small molecules play key roles in many biological
processes due to their ability to diﬀuse across cell membranes
[37]. These targets may be harmful, such as toxins and
carcinogens, or beneficial, such as drugs or nutrients. In cells,
small molecules serve as cell signaling molecules, pigments,
or as part of defense mechanisms [38]. In molecular biology,
they can be used as antibiotics or other important drugs
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Figure 2: Breakdown, by target type, of aptamers selected between
1990 and 2011. This list was generated using the Aptamer Base [41]
http://aptamerbase.semanticscience.org/ (accessed July 9, 2012)
(accessed July 9, 2012).
[39]. In the food industry, small molecules are important
for energy storage or can act as pesticides [40]. Aptamers for
small molecules may be applied to a wide variety of applica-
tions in medicine, agriculture, and environmental analysis.
Tables 2 and 3 list the small molecule targets for which DNA
and RNA aptamers, respectively, have been characterized.
2.2. Conceptual Challenges for Small Molecule Aptamers.
Although they represent a minor proportion of all aptamers,
small molecule-binding aptamers are among the most
successful and widely studied aptamers in the literature. For
example, the ATP aptamer is second only to the thrombin
aptamer in terms of the number of publications using the
sequence in an aptamer-based assay, sensor, or biosensor in
the last ten years. The cocaine and theophylline aptamers
are the fifth and seventh most frequently used aptamers for
biosensing, respectively [42]. It has already been described
that aptamers are ideal molecular recognition probes for
small molecules [8, 43], based on their ability to achieve a
remarkably high degree of selectivity. The first example of
this unparalleled selectivity was observed in 1994, when the
selected RNA aptamer for theophylline displayed a 10,000
times weaker binding aﬃnity to caﬀeine, a xanthine that dif-
fers by a single methyl group. This selectivity was found to be
a 10-fold improvement on the selectivity for the antibodies
for these targets [44]. Several groups have also exploited the
ability of aptamers to distinguish between small molecule
enantiomers [45]. Initially, several RNA aptamers displayed
partial discrimination between various L and D amino acids
[46, 47]. Then, in 1996, Geiger et al. [48] reported the
selection of RNA aptamers that bound to L-arginine with
high aﬃnity and enantioselectivity. More recently, enan-
tioselective DNA aptamers have been selected for the small
molecule drug (R)-thalidomide [49] and separate aptamers
have been identified for (S) and (R)-ibuprofen [50].
One possible explanation for the scarcity of new small
molecule aptamers is the impression that aptamers cannot
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Table 1: A list of modifications to the SELEX process and their descriptions.
Method Description Reference
Atomic force microscopy
(AFM)-SELEX
AFM-SELEX uses a dynamic atomic force microscopy tip to pick up and visualize aptamer-target
complexes. This SELEX requires only one round of selection.
[99]
Automated SELEX This SELEX uses automated systems for the procedure to reduce the time and labour required.
[34]
Blended SELEX
In this technique, a lead chemical compound is attached covalently or non-covalently to a nucleic
acid library. Each nucleic acid conjugate in the starting library is a variant of the chemical
compound moiety and allows up to 1015 variants of the small molecule to be screened for the most
active of these composite assemblies.
[100]
Cell-SELEX
Cell-SELEX generates aptamers that can bind specifically to a cell of interest. Commonly, a cancer
cell line is used as the target to generate aptamers that can diﬀerentiate that cell from other cancers
or normal cells.
[101]
Capillary electrophoresis
(CE)-SELEX
The separation of bound and nonbound oligonucleotides is performed using capillary
electrophoresis.
[102]
Chimeric SELEX
Chimeric SELEX uses two or more diﬀerent oligonucleotide libraries for production of chimeric
aptamers with more than one wanted feature or function. Each of the parent libraries will be
selected first to a distinct feature; the resulting aptamers are then fused together.
[103]
Conditional SELEX
This SELEX uses regulator molecules during the selection, thus, allowing aptamer binding to the
target to be regulated.
[104]
Counter selection/
subtractive SELEX
This technique employs additional rounds of SELEX to remove sequences that bind to similar target
structures.
[44]
Covalent/ Crosslinking
SELEX
This process is used to select aptamers that contain reactive groups which are capable of covalent
linking to a target protein.
[105]
Deconvolution SELEX
Deconvolution SELEX is used to generate aptamers for complex targets. Typically selection is
performed on mixtures (or a cell). Once aptamers have been generated, a second part of SELEX
involves discriminating which aptamers bind to which parts of the complex mixture.
[106]
Electrophoretic mobility
shift assay
(EMSA)-SELEX
The partitioning step of SELEX occurs through the use of electrophoretic mobility shift assay
(EMSA) at every round.
[107]
Expression cassette
SELEX
This is a special form of blended SELEX that involves transcription factors and optimizes aptamer
activity for gene therapy applications.
[108]
Fluorescence-activated
cell sorting (FACS)
SELEX
This SELEX makes use of fluorescence-activated cell sorting to diﬀerentiate and separate
aptamer-bound cells.
[59]
FluMag SELEX
Here the library is modified with fluorescein instead of radiolabels for quantification purposes.
Additionally, the target is immobilized to magnetic beads instead of agarose.
[109]
Genomic SELEX
The SELEX library is constructed from an organism’s genome and target proteins and metabolites
from the same organism are used to elucidate meaningful interactions.
[110]
In vivo SELEX
In vivo SELEX uses transient transfection in an iterative procedure in cultured vertebrate cells to
select for RNA-processing signals.
[111]
Indirect SELEX
The target used in the selection is not the aptamer binder; however, it becomes required for aptamer
binding to the new target.
[112]
Mod-SELEX
Mod-SELEX uses a library of oligonucleotides with chemical substitutions that result in
nuclease-resistant aptamers.
[113]
Multivalent aptamer
isolation (MAI) SELEX
This process is used to generate aptamer pairs for a given target. [114]
Microfluidics SELEX
This SELEX uses microfluidic technologies, creating an automatic, and miniature SELEX platform
for fast aptamer screening. [115, 116]
Monolex
Monolex involves a single aﬃnity chromatography step, followed by physical segmentation of the
aﬃnity material, to obtain the highest aﬃnity aptamers.
[117]
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Table 1: Continued.
Method Description Reference
Multiplexed
massively
parallel SELEX
This allows analysis of large numbers of transcription factors in parallel through the use of
aﬃnity-tagged proteins, bar-coded selection oligonucleotides, and multiplexed sequencing.
[118]
Multi-stage
SELEX
Multistage SELEX is a modified version of chimeric selex. Here, the fused aptamer components then
go through an additional selection with all the targets.
[119]
Negative
selection
An additional step, performed typically at the beginning of selection, removes sequences that have
an aﬃnity for the selection matrix.
[48]
Next generation
SELEX
This SELEX uses designed oligonucleotide libraries that tile through a pre-mRNA sequence. The
pool is then partitioned into bound and unbound fractions, which are quantified by a two-color
microarray.
[120]
Non-SELEX
(NCEEM)
This process involves repetitive steps of partitioning with no amplification steps. [121]
Photo SELEX
Aptamers bearing photo-reactive groups that can photo cross-link to a target and/or photo activate a
target molecule are used.
[122]
Primer-free
SELEX
This SELEX involves removal of the primer-annealing sequences from the library prior to selection,
preventing unwanted primer-based secondary structures.
[123]
Serial analysis of
gene expression
(SAGE) or high-
throughput
SELEX
SAGE SELEX links oligomers from SELEX with longer DNA molecules that can be eﬃciently
sequenced.
[124]
Spiegelmer
technology
The aptamer selection is performed with the natural D-nucleic acids but on the opposite
enantiomer of the chiral target molecule. After sequencing, the aptamers are synthesized as
L-isomers for binding to the desired enantiomer of the target.
[125]
Slow oﬀ-rate
modified
aptamers
(SOMAmer)
The selection is performed with oligonucleotide libraries that are uniformly functionalized at the
5′-position resulting in high-quality aptamers.
[28]
Tailored SELEX
This is an integrated method to identify aptamers with only 10 fixed nucleotides through ligation
and removal of primer binding sites within the SELEX process.
[126]
Target expressed
on cell surface
(TECS) SELEX
Recombinant proteins on the cell surface are used directly as the selection target. [127]
Tissue-SELEX This method is for generating aptamers capable of binding to tissue targets.
[106]
Toggle-SELEX The selection is performed on diﬀerent targets in alternating rounds.
[128]
Yeast Genetic
SELEX
This method optimizes in vitro selected aptamers by creating a library of degenerate aptamers and
performing a secondary selection in vivo using a yeast three (one)-hybrid system.
[129]
bind these smaller targets with the high aﬃnity required
for most sensing applications. Work by Carothers et al.
attempted to determine the eﬀect of target structure and size
on binding aﬃnity [51]. Using aptamers for 6 small molecule
targets from the literature, as well as aptamers obtained
from his own selections for two other small molecules,
Carothers determined that the target molecular weight was
proportional to the resulting aptamer aﬃnity (larger targets
resulted in lower Kd values). This finding was consistent
with the findings of other studies between aﬃnity and target
mass [52]. However, the target theophylline which has a
very small mass (180 g/mol) did not follow this general
trend. It was therefore concluded that targets with fewer
rotatable bonds, and therefore fewer degrees of freedom,
can result in improved aptamer aﬃnity. Nevertheless, while
many aptamers that bind to small molecule targets display
aﬃnities in the low to mid micromolar range, there are
several aptamers that have recently been isolated with Kd
values in the low nanomolar range (e.g., BPA [53] and
oxytetracycline [54]). Furthermore, riboswitches, which are
widely considered as containing “natural aptamers,” bind
exclusively to small molecules and ions, and several of
these display remarkably strong binding. For example, the
guanine riboswitch has a Kd of 5 nM [55] and the thiamine
pyrophosphate-sensing riboswitch has an aﬃnity in the
picomolar range [56]. The glycine riboswitch is particularly
noteworthy for its ability to selectively bind to one of the
smallest target of any natural or artificial aptamer [57].
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Table 2: A listing of DNA aptamers reported in the open literature∗ (up until July 2012) that have been confirmed to bind to small molecule
targets. The dissociation constant (Kd), a measure of binding aﬃnity, is included as well as the year of aptamer development.
Target Binding aﬃnity (Kd) Year Reference
Reactive green 19 33 μM 1992 [130]
Adenosine monophosphate and adenosine triphosphate 6 μM 1995 [131]
L-arginine 2.5mM 1995 [132]
L-argininamide 0.25mM 1995 [132]
Anionic porphyrins 0.4–4.9 μM 1996 [88]
Sulforhodamine B 190 nM 1998 [61]
Cellobiose 600 nM 1998 [133]
7,8-dihydro-8-hydroxy-2′-deoxyguanosine 270 nM 1998 [134]
Cholic acid 5–67.5 μM 2000 [135]
Hematoporphyrin 1.6 μM 2000 [136]
L-tyrosinamide 4.5 μM 2001 [137]
Sialyllactose 4.9 μM 2004 [138]
Ethanolamine 6–19 nM 2005 [139]
(R)-thalidomide 1 μM 2007 [49]
Hoechst derivative 7e 878 nM 2007 [140]
17β-estradiol 0.13 μM 2007 [141]
Lys-Arg-Azobenzene-Arg 0.33 μM 2007 [142]
Tetracycline 64 nM 2008 [143]
L and D arginine 580–810 μM 2008 [144]
Daunomycin 10 nM 2008 [145]
Oxytetracycline 10 nM 2008 [54]
Ochratoxin A 200 nM 2008 [26]
Dopamine 700 nM 2009 [146]
8-hydroxy-2′-deoxyguanosine 100 nM 2009 [147]
Diclofenac 42.7–166.34 nM 2009 [148]
(S) and (R)-ibuprofen 1.5–5.2 μM 2010 [50]
Adenosine triphosphate 3.7 μM 2010 [31]
Fumonisin B1 (FB1) 100 nM 2010 [7]
Acetamiprid 4.98 μM 2011 [149]
Kanamycin 78.8 nM 2011 [150]
L-tryptophan 1.757 μM 2011 [151]
Bisphenol A 8.3 nM 2011 [53]
Ochratoxin A 96–293 nM 2011 [152]
Phenylphosphonic dichloride >50 μM 2011 [153]
Organophosphorus pesticides (phorate, profenofos, isocarbophos and omethoate) 0.8–2.5 μM 2012 [154]
Polychlorinated biphenyls (PCB77) 4.02, 8.32 μM 2012 [155]
Polychlorinated biphenyls (PCB72 and PCB106) 60–100 nM 2012 [156]
Ampicillin 9.4–13.4 nM 2012 [157]
∗Only aptamer sequences that have experimentally determined Kd values were included in this table.
Nature’s eﬀectiveness at developing small molecule aptamers
should provide an indication that there is considerable
untapped potential in this field.
In the early 1990s, in an eﬀort to promote the power
of SELEX, numerous papers and reviews boasted that in
vitro selection is facile, inexpensive, and fail-safe, which may
have contributed to little interest in publications for new
selections. On the contrary, SELEX can be very laborious
and it has been estimated that less than 30% of selections
result in aptamers [28]. Additionally, patents for virtually
every application of aptamers have placed a stranglehold
on aptamer innovation [58]. As a result, very few research
groups have chosen to invest the time and expense to
develop aptamers for new small molecule targets, especially
considering the unique technical challenges that arise when
selecting for small molecule binding aptamers, as is discussed
in the next section.
3. Technical Challenges for
Small Molecule Aptamers
3.1. Target Immobilization. The separation of target-bound
sequences from those with no aﬃnity for the target is a
critical step in the SELEX process. For protein targets,
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Table 3: A listing of RNA aptamers reported in the open literature∗ (up until July 2012) that have been confirmed to bind to small molecule
targets. The dissociation constant (Kd), a measure of binding aﬃnity, is included as well as the year of aptamer development.
Target Binding aﬃnity (Kd) Year Reference
Organic dyes 100–600 μM 1990 [158]
D-tryptophan 18 μM 1992 [46]
L-valine 2.9mM 1994 [159]
Theophylline 100 nM 1994 [44]
Cyanocobalamin 88 nM 1994 [160]
L-citrulline 62–68 μM 1994 [47]
Flavin mononucleotide 0.5 μM 1994 [161]
Flavin adenine dinucleotide 137–273 μM 1994 [161]
Kanamycin A ≤300 nM 1995 [162]
Neomycin 100 nM 1995 [163]
Tobramycin 2–3 nM 1995 [164]
Lividomycin ≤300 nM 1995 [162]
Nicotinamide adenine dinucleotide 2.5 μM 1995 [165]
Riboflavin 1–5 μM 1995 [165]
Biotin 5 μM 1995 [166]
L-arginine 330 nM 1996 [48]
Dopamine 2.8 μM 1997 [167]
7-methyl-guanosine 5 μM 1997 [168]
CCdApPuro 10 nM 1997 [169]
Chloramphenicol 25–65 μM 1997 [170]
Viomycin 11–21 μM 1997 [171]
Sulforhodamine B 310 nM 1998 [172]
Streptomycin 1–10 μM 1998 [173]
L-isoleucine 200–500 μM 1998 [174]
7,8-dihydro-8-hydroxy-2′-deoxyguanosine (8-oxodG) 0.27–2.8 μM 1998 [134]
Xanthine 3.3 μM 1998 [175]
Guanine 1.3 μM 1998 [175]
Malachite green ≤1 μM 1999 [176]
Phosphatidylcholine ≥100 μM 1999 [177]
Cyclic adenosine monophosphate 10 μM 2000 [178]
Adenosine triphosphate 127–223 μM 2000 [179]
L-tyrosine 35 μM 2000 [180]
S-adenosyl homocysteine 0.2–0.8 μM 2000 [181]
Neomycin 1.8 μM 2000 [182]
Moenomycin A 300–400 nM 2001 [183]
Sialyl Lewis X 0.085–10 nM 2001 [184]
Tetracycline 1 μM 2001 [185]
Kanamycin B 180 nM 2001 [186]
Adenine 10 μM 2002 [187]
Flavin adenine dinucleotide 50 μM 2002 [188]
L-isoleucine 1–7mM 2003 [189]
Adenosine triphosphate 2 μM 2003 [190]
Morpholine-based GTP analog 20, 33 μM 2003 [191]
4,4′-methylenedianiline 0.45–15 μM 2004 [192]
Tobramycin 30–100 nM 2004 [34]
Kanamycin 10–30 nM 2004 [34]
Adenosine triphosphate 5 μM 2004 [193]
Isoleucine 0.9mM 2005 [194]
L-histidine 8–54 μM 2005 [195]
Codeine 2.5–4 μM 2006 [33]
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Table 3: Continued.
Target Binding aﬃnity (Kd) Year Reference
Mesomesoprotoporphyrin IX 188–445 nM 2006 [87]
Thyroxine 50 μM 2007 [196]
Tobramycin 16 μM 2007 [197]
10-carboxy-2,7-di-t-butyl-trans-12c,12d-dimethyl-12c,12d-dihydrobenzo[e]pyrene 2.7 μM 2007 [198]
Dimethylindole red 87 nM 2008 [199]
Cyanine 3 dye 60 μM 2010 [200]
Aniline-substituted sulforhodamine analogue 3.5 μM 2010 [201]
Atrazine 2 μM 2010 [202]
Sphingosylphosphorylcholine 20–250 nM 2010 [203]
Black hole quencher 4.7 μM 2011 [204]
4-dimethylaminobenzylidene imidazolinone 464 nM 2011 [205]
Glutathione 41.8, 48.9 nM 2011 [206]
Heteroaryldihydropyrimidine 50 nM 2011 [207]
∗Only aptamer sequences that have experimentally determined Kd values were included in this table.
partitioning can be achieved using a matrix that selectively
adsorbs the target and any interacting aptamer sequences.
For example, nitrocellulose filters are a cheap and convenient
matrix for this purpose due to their nucleic acid permeability
and their ability to retain proteins by hydrophobic adsorp-
tion. With cell targets, partitioning can be accomplished by
centrifugation, fluorescence activated cell sorting (FACS),
[59] or by gentle washing of adherent cells [13]. In the case
of both these target types, the selection can be accomplished
without chemical modification of the target; this is ideal since
it increases the likelihood of finding aptamers capable of
binding the molecule in its unaltered form. This is typically
not possible with small molecule aptamer selections. Thus,
the primary complication arises from the need to immobilize
the target to a solid support matrix, for example, magnetic
beads, acrylic beads, agarose/sepharose, to facilitate the
partitioning process. Early small molecule aptamers were
selected for targets for which premade agarose material was
commercially available [10]. In the absence of commercially
available material, there is a wide array of conjugation
chemistries that are available for preparing these materials
for SELEX experiments. However, these are all dependent on
the presence of certain functional groups that allow for cou-
pling, which are not always present on the desired target. For
cases where conjugation is possible, the proportionally large
amount of column material, in comparison to the target,
that is presented to the nucleic acid pool during each SELEX
round can result in high nonspecific binding of the library.
As chemical modification of the target is required to facilitate
column immobilization, the library is exposed to chemically-
modified target rather than the desired, unmodified target
molecule, increasing the likelihood of selecting sequences
that display binding properties towards the matrix and/or
the linker arm. Despite negative selection steps, carry-over
of such sequences is diﬃcult to avoid [60]. Many aptamer
applications, particularly those in vivo, require the selected
sequences to bind the target free in solution. Therefore, any
aptamer aﬃnity derived from partial binding to thematrix or
from chemical modifications will reduce the functionality of
the aptamer in the intended applications. For example, the
published rhodamine aptamer displays a weaker binding to
the target rhodamine when in solution compared to when it
is immobilized on the matrix used in the selection [61].
3.2. Measurement of Binding Aﬃnity (Kd). While new meth-
ods for the determination of binding aﬃnity are constantly
being developed, this is often the limiting factor in the rapid
development and testing of aptamers. This is particularly
true for small molecule binding aptamers. To measure Kd,
a constant concentration of either the aptamer or target
is titrated with an increasing concentration of the other
component to yield a binding isotherm. A list of common
methods for determining aptamer binding aﬃnity can be
found in the Table 4. A brief evaluation of their applicability
to small molecule binding aptamers is also provided below.
As can be seen in Table 4, relatively few of these common
Kd methods are eﬀective for measuring aptamer binding to
small molecules. Separation-based techniques are among the
most common approaches for determining binding aﬃnity,
and many of these are more challenging for small molecule
targets than for proteins. In particular, separation-based
methods that rely on a dramatic change in the size of the
aptamer-target complex upon target binding are of limited
use when the target is much smaller than the aptamer.
Other methods require that the target has some intrinsic
fluorescence/absorbance, which is often not the case. For
targets lacking these properties, an alternative is to label
the target, which can aﬀect the chemical properties of the
small molecule and interfere with aptamer binding. Surface
mass-sensitive detection methods such as QCM and SPR
are typically limited to large targets such as proteins [62].
These approaches generally require one binding partner to be
tethered to the surface. In cases where the aptamer is surface-
bound, the sensitivity of the technique may be compromised
by the small overall mass change caused by small molecule
binding. As an alternative, the target could be attached
to the surface, but once again this chemical modification
of the target can negatively impact binding aﬃnity. Other
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Table 4: Methods for determining aptamer binding aﬃnity.
Method Description of method and applicability to small molecules
Sample
reference
Spectroscopy-based methods
Fluorescence intensity
The fluorescence of the aptamer or target may be quenched or increased upon
binding. This method requires a fluorescent small molecule target or requires
labelling of the target.
[208]
Fluorescence polarization
A fluorophore is excited with polarized light and, due to rotational diﬀusion, the
size of the fluorophore will dictate the proportion of polarized light that is emitted.
This method requires a fluorescent small molecule target or target labelling. It can
be used with a fluorescently tagged aptamer, however, the method is less sensitive as
the overall change in mass upon binding a small molecule will be less dramatic.
[209]
UV-vis absorption
This method requires a change in intensity or wavelength of absorption in either
the aptamer or target’s UV-vis spectrum. In some cases, melting studies can be used
to determine Kd .
[210]
Circular dichroism (CD)
CD refers to the diﬀerential absorption of left and right circularly polarized light.
Upon aptamer binding to the target, the CD spectra may change but a significant
diﬀerence in conformation upon target binding is required for this method to have
good sensitivity.
[211]
Nuclear magnetic spectroscopy
(NMR)
By comparing the heteronuclear single quantum coherence spectroscopy (HSQC)
of individual amide protons in the free and bound aptamer, it is possible to observe
changes in the chemical shifts of the peaks. This method requires conformation
changes in the aptamer for good sensitivity.
[212]
Mass-sensitive surface-based measurements
Surface plasmon resonance (SPR)
Either the target or aptamer can be coupled to a chip; by flowing various
concentrations of the nontethered ligand, changes in refractive index can be
measured as the aptamer-target complex forms. If the small molecule target is
immobilized, its ability to bind to the aptamer may be compromised.
Immobilization of the aptamer, however, leads to a less sensitive measurement as
the smaller target will cause less of a change at the surface.
[33]
Quartz crystal microbalance
(QCM)
This method uses piezoelectric crystals to correlate the mass accumulated (target
binding) on the surface with a decrease of the resonance frequency of the quartz
crystal. Once again, small molecule target immobilization could aﬀect binding
aﬃnity. Immobilization of the aptamer leads to a less sensitive measurement
because there will less of a mass change upon target binding.
[213]
Separation-based methods
High-performance liquid
chromatography (HPLC)
Zone separations of the free aptamer, target, and aptamer-target complex can be
used to assess the equilibrium distribution of these components. This method is
particularly diﬃcult with small molecule targets as they have less of an eﬀect on the
separation of aptamer-target complex from the free aptamer.
[214]
Capillary electrophoresis (CE), kinetic
capillary electrophoresis (KCE),
aﬃnity probe capillary electrophoresis
(APCE)
This method is similar to HPLC except that it using an electric field to separate the
components of the mixture by size and charge. Small molecule targets can be a
challenge, typically requiring labeling of the small molecule although label-free
KCE UV has recently been described. Once again, separation of the aptamer-target
complex from the free aptamer can be more diﬃcult in the case of small molecule
targets.
[64, 215,
216]
Microfree-flow electrophoresis
(μ-FFE)
This technique separates aptamer and aptamer-target complex based on their
electrophoretic mobilities. Sample is continuously streamed into a planar flow
channel while an electric field is applied perpendicularly to the direction of flow,
deflecting analyte streams as they travel through the flow channel according to their
mobility. Once again, this method is less eﬀective with small molecule targets.
[217]
Equilibrium dialysis
Equilibrium dialysis allows the aptamer, target and the complex to equilibrate in a
two compartment cell separated by a semipermeable membrane that allows only
the smallest component to pass through. This method can be hampered by
nonspecific adsorption of small molecule targets to the membrane.
[26]
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Table 4: Continued.
Method Description of method and applicability to small molecules
Sample
reference
Ultrafiltration/nitrocellulose filtration
This method is similar to dialysis. The aptamer and target are incubated to allow
binding. The fraction of the smallest unbound component is forced through a filter
and measured. Once again, nonspecific adsorption to the membrane can cause this
method to be unreliable.
[218]
Aﬃnity chromatography
Either the target or aptamer is covalently immobilized to a solid-phase support. The
other component is incubated with the support and the amount of binding is
calculated. As with other methods, chemical modification of the target or the
aptamer to allow for immobilization can aﬀect binding.
[7]
Electrophoretic mobility shift assay
(EMSA)
The presence of the target will cause an increase in molecular weight of the
aptamer-target complex, resulting in a change in electrophoretic mobility and a gel
shift. This approach is not eﬀective with small molecule targets unless a significant
conformational change is observed upon binding.
[219]
Optical thermophoresis
Based on the directed movement of molecules along temperature gradients, the
thermophoresis of an aptamer typically diﬀers significantly from that of an
aptamer-target complex because of changes in size, charge, or solvation energy.
This method requires fluorescent labelling which could aﬀect binding. Also, it
could be less sensitive for small molecule aptamers due to the smaller change in
mass upon target binding.
[220]
Other methods
Isothermal titration calorimetry (ITC)
This method allows simultaneous determination of Kd , stoichiometry, and
thermodynamic properties. It relies on the fact that formation of the aptamer-target
complex is an exothermic process. Eﬀective for small molecule aptamers,
particularly if a large conformational change occurs upon target binding.
[221]
High-throughput aﬃnity quantitative
PCR binding assay
With this method, an aptamer duplex is incubated with the target. The
concentration of aptamer released by this binding event is then measured using real
time PCR.
[222]
In-line probing
Spontaneous cleavage of the RNA backbone is aﬀected by local structural
characteristics, which in turn are impacted by target binding. Can be eﬀective for
small molecule aptamers but requires conformational changes upon target binding
and is only applicable to RNA aptamers.
[223]
Footprinting assays
This method determines the region of aptamer sequence where target binding
occurs by exploiting that the target may protect the aptamer from enzymatic
cleavage/chemical reactions. Footprinting assays are easier with larger targets or
require conformational changes with target binding.
[224, 225]
methods that detect a change in aptamer conformation
upon binding to target can be applicable to small molecule
aptamers, but measurable conformation change is not a
universal property of all aptamers [63]. Some recent reports
of approaches for determining aptamer binding aﬃnity
have recognized the unique challenges for small molecule
aptamers and attempted to address them using more innova-
tive approaches such as automatedmicrochip electrophoresis
and atomic force spectroscopy, although no technique can be
considered generally applicable to small molecule aptamers
at this stage [64, 65].
4. Opportunities for Small Molecule Aptamers
While aptamer technology has existed for over two decades,
the challenges imposed on the development of aptamers for
small molecules has resulted in very few novel aptamers that
can bind to practical small molecular targets. Nevertheless,
there are many opportunities for the innovative application
of small molecule binding aptamers in biosensing and
chemical biology. A diverse range of natural and synthetic
compounds fall under the designation of small molecules,
including organic compounds, amino acids, steroids, car-
bohydrates, and nucleotides. These molecules play a variety
of beneficial roles; they are therapeutics, dyes, cofactors,
metabolites, and neurotransmitters. Unfortunately, they
may also be harmful substances, such as pollutants, food
adulterants, carcinogens, and drugs of abuse. There are
many reasons why eﬀective tools for the detection of
small molecules are needed now more than ever before.
These include the growing recognition of the role of small
molecules in biological systems, the extensive application
of synthetic small molecules as drugs, and the increasing
need to monitor contamination our environment and food
supply. Many examples of aptamer-based sensing approaches
have been designed for the detection of small molecules,
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Figure 3: Illustration of sample electrochemical, fluorescence, and
colorimetric assays using the structure switching strategy and small
molecule-binding aptamers.
however, most are proof-of-concept systems using the ATP,
cocaine, or theophylline aptamer. Electrochemical, fluores-
cence, colorimetric, and other approaches that have been
employed for aptamer-based sensing have been highlighted
in several recent reviews [66–69]. However, the general
applicability of many of these biosensors to small molecule
targets, other than the three main targets mentioned, has
yet to be confirmed. As shown in Tables 2 and 3, however,
there are many small molecule aptamer sequences that are
available for biosensor development. Several of these targets
are relevant to applications in environmental monitoring,
agriculture, food safety, and medicine [70]; this is a clear
motivation to move aptamer-based biosensing past the few
proof-of-concept systems and to validate aptamer-based
sensing approaches for real-world bioanalytical applications.
One notable approach to small-molecule biosensing
has been the “structure-switching” strategy, described by
Li and colleagues, which relates to the unique ability of
nucleic aptamers to bind to both their cognate target
and to a complementary sequence [71]. This ability to
switch from a nucleic acid duplex to an aptamer-target
complex, and its concomitant structural changes, have been
shown to be a generally applicable method for converting
a recognition event into detectable signal. As such, it has
been applied to several fluorescence, electrochemical, or
colorimetric (nanoparticle-based) assays (see Figure 3). This
strategy is particularly appealing given that a large confor-
mational change upon target binding is virtually guaranteed,
thus many of the typical limitations encountered in small
molecule detection are avoided. Both DNA and RNA
aptamers can be employed in this approach [72] and it has
been used in solution and on surfaces [73]. Although many
reports use this methodology for the sensing of adenosine
or ATP [71], this method has been applied to detect several
other small molecule targets including theophylline [72],
cocaine [74], histidine [75], OTA [76], L-argininamide [77],
tyrosinamide [78], GTP [79], and arginine [80].
Recent reviews have examined how aptamers can be
combined with other functional moieties without aﬀecting
their ability to recognize and bind to their cognate target [81,
82]. This property can allow aptamers to serve as regulatory
elements for nucleic acid enzymes (either natural ribozymes
or synthetic DNAzymes) or other actuator parts, allowing
control of a variety of functions such as gene-expression reg-
ulation [83]. Small molecule-binding sequences are particu-
larly convenient for the preparation of these chimeras. This is
perhaps not surprising considering that natural riboswitches,
which are known to be key regulators of several biosynthetic
pathways, contain an aptamer domain that serves as a high
aﬃnity sensor for a specific small molecule. In one of the
original examples of these chimeric systems, one of the stem-
loop sections of the widely studied hammerhead ribozyme
was replaced with the ATP-binding aptamer. As a result, ATP
binding was required for activation [84]. A similar approach
can be applied to the development of allosteric aptamers for
sensing. Conjugation of the malachite green aptamer to the
flavin mononucleotide (FMN) aptamer created a FMN sen-
sor where binding of malachite green and the concomitant
increase in fluorescence could only be achieved after FMN
bound to its aptamer domain [85]. ATP and theophylline
sensors were also made using the same approach. This
strategy has been suggested for the fluorescence detection
of cellular metabolites; a combination of the endogenously
expressed aptamer conjugate and cellular dyes could enable
intracellular detection. Thus, the continued development
of biologically relevant small molecule aptamers for these
chimeric systems is important in order to enable further
advances in areas such as in vivo imaging and synthetic
biology.
Small molecule-binding-aptamers can also serve as
important tools for elucidating the role that biologically-
important small molecules play in modulating critical cel-
lular regulatory circuits. Intramers, aptamers specific for
intracellular target proteins, have already been shown to be
useful tools for probing important protein-based networks in
vivo [86]. By perturbing the intracellular pools of physiolog-
ically important small molecules, small-molecule-binding
aptamers also have the potential to improve our understand-
ing of biological systems. This strategy has been explored
by Marletta using intracellular expression of a heme-bind-
ing RNA aptamer to predictably modulate E. coli heme
biosynthesis as a model for a product feedback inhibited
system. This group demonstrated that in vitro selected,
heme-binding RNA aptamers could specifically sequester
intracellular heme when expressed in vivo and perturb
the heme-mediated inhibition of the heme biosynthetic
pathway in ameasurable way [87]. Using heme-bindingDNA
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Figure 4: (a) Confirmation of aptamer-mediated inhibition of hemozoin formation within parasite lysates. Heme-binding DNA aptamers
(OKA 26-5 and 26-3; PS26, PS21, and PS2M) inhibit hemozoin formation but control oligonucleotides (PS2M Mod and PS2R) have no
eﬀect. (b) The growth of parasites incubated in red blood cells that had been preloaded with nuclease resistant DNA aptamers (PS2M idT
and PS26-idT) is significantly inhibited in comparison to those exposed to red blood cells loaded with control oligonucleotides (PS2M Mod-
idT). Used with permission from PNAS.
aptamers [88], Marletta and colleagues also demonstrated
that aptamers can successfully control an essential, P. fal-
ciparum-specific metabolic pathway [89]. In this study, the
pathway of interest was the parasite’s heme detoxification
pathway, a key target for malaria controls. Hemoglobin
ingested by the parasite is degraded in vacuolar structures
at low pH (between 4.5 and 5.5), releasing free heme.
This free heme is cytotoxic, thus, heme detoxification by
polymerization into hemozoin is a critical process for
plasmodia survival. The heme-binding DNA aptamers were
shown to interfere with hemozoin formation in two in vitro
assays, one using a model lipid-catalyzed system and the
other using parasite-derived lysates containing the native
hemozoin formation components. IC50 values for inhibition
by the aptamers were comparable to that of chloroquine,
a known inhibitor of hemozoin production. Additionally,
when preloaded into red blood cells, nuclease resistant heme-
binding aptamers induced parasite toxicity in a manner con-
sistent with inhibiting the hemozoin production process in
early stage parasites (see Figure 4). These examples show the
potential utility of small molecule-binding aptamers as new
chemical tools for probing biophysical processes as well as
their potential use as leads in antimalarial drug development.
Recently, the in vivo utility of a dopamine-binding DNA
aptamer as a tool to investigate neurobiological processes was
demonstrated in a preclinical animal model of schizophrenia
[90]. In a similar fashion as the heme example, the role of
the dopamine aptamer was to sequester excess dopamine in
a particular brain region (the nucleus accumbens) and to
monitor whether an abnormal behavior could be reversed
as a result. The drug MK-801, an N-Methyl-D-aspartate
(NMDA) receptor antagonist, has been used to model
the cognitive dysfunction observed in individuals with
schizophrenia. In this schizophrenia model, rats are trained
to press a bar for chocolate pellet rewards. After 5 days of
training, the rats undergo an “extinction” test, where no
chocolate is presented upon lever pressing.While normal rats
quickly realize this and stop pressing the lever, rats under
the influence of MK-801 show a cognitive defect known as
perseveration, meaning that they continued to press the lever
at a high rate and are unable to inhibit this behavioral ten-
dency. This defect has been linked to high levels of dopamine
in the nucleus accumbens region of the brain. The ability
of a dopamine-binding DNA aptamer to reverse these MK-
801-induced cognitive deficits when injected directly into
the nucleus accumbens was determined. Figure 5(a) shows
that injection of the dopamine aptamer (filled triangles)
reversed the MK-801-induced elevation in lever pressing
to levels as seen in rats not treated with MK-801 (empty
squares, X with dashed line). Injection of buﬀer (empty
diamonds) or of a random oligonucleotide (dashed line)
had no eﬀect on moderating the pressing behavior. Thus, it
appears that the aptamer was successful in sequestering the
excess dopamine within the nucleus accumbens, resulting
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Figure 5: (a) Pretreatment of animals with the dopamine aptamer reversed the eﬀects of MK-801 administration. Animals given MK-801
(empty diamonds; 0 nM/MK) show higher cumulative presses in this behavioural test in comparison to animals not given this drug (empty
squares, dashed line; 0 nM/Saline). The group receiving aptamer pretreatment (filled triangles; 200 nM/MK), however, showed similar levels
of cumulative presses as those that were not given any MK-801. A random oligonucleotide pretreatment, however, had no dampening eﬀect
on the number of presses (X with dashed line; Random/MK). (b) Aptamer pretreatment (200 nM/MK) did not significantly aﬀect locomotor
activity as measured by distance traveled in an elevated cross maze. Used with permission from PLoS One.
in “normal” behavior. Interestingly, it was also shown that
the aptamer treatment did not impair locomotor activity
in the animals (Figure 5(b)). The near-selective eﬀect of
the aptamer on reversing cognitive deficits without drastic
negative motor consequences lends support for the use of
DNA aptamers in the further study of preclinical animal
models of mental health disease and as possible drug leads.
New neurotransmitter-binding aptamers, as well as strategies
for the delivery of aptamers across the blood-brain-barrier,
will be required to realize the full potential of aptamers in
this regard.
5. Conclusions and Outlook
The selection and application of small molecule-binding
aptamers come with a unique set of challenges that have
hampered their research and commercialization. Neverthe-
less, eﬀorts to expand the suite of aptamers for pertinent
small molecules need to continue. A major bottleneck in
small molecule aptamer development and application occurs
at the point of Kd determination. Approaches for binding
aﬃnity measurement that are more generally applicable to
small molecule targets are required. Additionally, there is a
negative perception that there are published aptamers that
have little aﬃnity to their targets [91]. Because of these
issues associated with Kd measurements for small molecules,
several complementary methods may be required in order
to achieve a true sense of the aptamer binding aﬃnity for
its target. Ideally, these methods should allow aptamer-target
binding to occur free in solution, to remove any contribution
from matrix binding. A new aptamer database is available
(http://aptamerbase.semanticscience.org/) containing valu-
able information about the experimental conditions under
which the aptamers were selected and their binding aﬃnity
quantified [41]. Eﬀorts to mine this data to better tailor
SELEX and binding aﬃnity experiments for small molecules
is currently underway. Aptamer-based assays also need to
begin to move away from the proof-of-concept targets
and exploit the largely untapped resource of existing small
molecule-binding aptamers. Signs of this shift to more
relevant aptamer-based assays can be seen with the large
number of biosensors developed using the ochratoxin A
(OTA) aptamer. This small molecule mycotoxin contami-
nates a wide variety of food commodities such as cereals
and wine. Several recent reports have used OTA-binding
sequences [26] to develop aﬃnity clean-up columns [92, 93]
and biosensors [94–98] for evaluation under actual food
testing conditions. Applications of small molecule-binding
aptamers in other burgeoning areas, such as metabolomics,
drug discovery, and synthetic biology, could also soon see
dramatic growth. Continued eﬀort in the development of
aptamers for important small molecules is required in order
for this field to realize its full potential.
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